FDA's increased scrutiny could be barrier to fecal transplants

06/4/2013 | NBC News

Providers who conduct fecal transplants must submit investigational new drug applications, according to the FDA, and physicians say the requirement could bring the procedures to a halt. The method is used to introduce a new population of bacteria in the treatment of patients with gastrointestinal symptoms, particularly those caused by Clostridium difficile. The FDA is seeking to "provide regulatory clarity" and to ensure valid trials, agency spokesman Curtis Allen said.

View Full Article in:

NBC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC